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ABSTRACT:
BILR 355 is an inhibitor of the human immunodeficiency virus-1. BILR 355 exhibited a nonlinear pharmacokinetic profile and low exposure after oral administration to humans. This paper describes the in vitro metabolism of BILR 355, which is correlated with the in vivo nonlinearity findings. Our in vitro studies had demonstrated that BILR 355 was extensively metabolized by cytochrome P450 3A. Consequently BILR 355 was concomitantly administered with ritonavir (RTV) in attempt to boost systemic exposure which did occur in humans. In addition, the expectation was that the overall metabolism of BILR 355 would be decreased with concomitant administration of RTV. Subsequent metabolite profiling was performed using human plasma samples obtained from clinical Phase Ib studies with concomitant administration of BILR 355 and RTV. A total of eighteen metabolites were observed. Their structures were proposed based on high performance liquid chromatography-tandem mass spectrometry technologies and ten metabolites were confirmed by comparison with synthetic standards. Surprisingly, a disproportionate human metabolite, BILR 516, was uncovered during this metabolite profiling study and PK analysis of BILR 516 showed that it had a longer half-life and higher exposure than the parent compound at steady state. Interestingly, BILR 516 was not detected in human plasma when BILR 355 was administered alone. So while RTV boosted the exposure of BILR 355, it resulted in a significant metabolic switching of BILR 355. Overall, this paper demonstrates an unusual example of metabolic switching and raises the concern on the consequence of metabolic switching during dug development.
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Introduction
The human immunodeficiency virus (HIV)-1 infection remains a major worldwide health issue. The current antiretroviral therapy has dramatically reduced morbidity and mortality among HIV-infected patients and significantly modified the course of HIV disease into a manageable chronic disease with longer survival and improved quality of life of the patients (Palella et al., 1998; Hogg et al., 1998; Moreno et al., 2010) . However, resistance has emerged to almost all of these antiretroviral agents, sometimes rendering them ineffective (Hammer et al., 2008) . First generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) are particularly vulnerable, since resistance may emerge with a single resistance codon alteration and the emergence of drug resistant HIV-1 variants is fairly rapid (De Clercq, 1998) . In addition, extensive cross-resistance among NNRTIs was observed, resulting in a loss of the efficacy of subsequent NNRTI treatment (de Béthune, 2010) . Therefore, it is essential to have additional NNRTIs developed to effectively treat patients with NNRTI-resistant HIV (De Clercq, 2004) . BILR 355 is a second generation NNRTI (Boone, 2006; Bonneau et al., 2005) . The in vitro results showed that the EC 50 of BILR 355 was 0.26 ng/mL (0.59 nM) against wild type HIV-1 and ranged from 1.5 to 13 ng/mL (3.4 nM to 29 nM) against clinically common single and double NNRTI mutations (Bonneau et al., 2005) . A clinical study revealed that BILR 355 was rapidly absorbed after a single oral dose in healthy volunteers with the mean time to maximum drug concentration (T max ) of 0.5 to 1.5 h. However, thereafter the concentrations of BILR 355 rapidly declined, resulting in a short terminal half-life (T 1/2 ) of approximately 2 to 4 h (Huang et al., 2008) . Our in vitro data demonstrated significant metabolism of BILR 355 by cytochrome DMD #44354 6 boost plasma concentrations and to increase T 1/2 of HIV protease inhibitors (Hull and Montaner, 2011) . With concomitant administration of RTV, the T 1/2 of BILR 355 increased to approximately 10 to 16 hours and the maximum plasma concentration (C max ) increased 2-to 5-fold with the area under the plasma concentration-time curve from time zero to infinity (AUC 0-∞ ) increasing 15-to 30-fold (Huang et al., 2008) ; a profile more consistent with once daily dosing.
However, this combination created an unexpected problem, a disproportionate human metabolite (BILR 516), as a result of significant metabolic switching of BILR 355. The current manuscript describes the in vitro metabolism of BILR 355 by CYP3A and identification of the metabolites resulting from metabolic switching due to inhibition of CYP3A by the concomitantly administered RTV.
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8 MS/MS (high performance liquid chromatography-tandem mass spectrometry). The experiment was performed in duplicate for each lot of HLMs.
Metabolism of BILR 355 by Recombinant CYP Isoforms. BILR 355 (1 or 10 µM) was incubated with recombinant CYP isoforms (rCYP1A2, rCYP2B6, rCYP2C9, rCYP2C19, rCYP2D6, and rCYP3A4) in a 0.1 M potassium phosphate buffer with 5 mM of MgCl 2 at pH 7.4.
The final rCYP concentrations were 50 pmol/mL and the total incubation volume was 800 µL.
The reactions were pre-incubated at 37 ºC for 5 min before the addition of NADPH at a final concentration of 2 mM. Control samples were prepared identically, except that non-transfected insect cell microsomal protein was substituted for individual recombinant CYP isoforms. The (5 µM) for CYP2D6, and ketoconazole (1 µM and 3 µM) for CYP3A4 (Chauret et al., 1997; Bourrié et al., 1996) . The incubation conditions and sample analysis were as described above for HLMs.
The experiment was performed in triplicate. (Huang et al., 2009) . Steady state levels of BILR 355 were achieved by Day 7 and only one dose of BILR 355 and RTV was given on day 7 to obtain a full PK profile. Intensive PK samples were taken on Day 1 at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 9, and 12 h and on Day 7 at 0, 0. 25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 16, 24, 48, and 72 h following drug administration. Plasma samples from different subjects were pooled at T max (1.5 h) and two later time points (6 h and 24 h) on day 7. The zero hour samples at Day 1 were also pooled and used as control samples for metabolite identification. The pooled plasma samples were vortexed thoroughly and 300 µL aliquots were transferred to Eppendorf tubes. (Obach et al., 1997) . The following constants were used to estimate CL int, in vivo from CL int, in vitro: a value of 45 mg of microsomal protein/g of liver (Houston, 1994) , 1800 g of human liver weight, and average 70 kg of human body weight (Davies and Morris, 1993 stirred model was applied and CL h (mL/min/kg) was calculated using the following equation (Pang and Rowland, 1977) : Four lots of pre-characterized HLMs were selected based on their testosterone 6β-hydroxylase activities representing a range from low to high CYP3A4 activities from available individual lots of human liver microsomes. Protein linearity was evaluated. Rates of metabolism were linear with concentrations of HLMs over the range of 0.5 mg/mL to 2 mg/mL microsomal protein.
Therefore, the amount of microsomal protein in the K m and V max assay was adjusted within the range of 0.5 to 2 mg/mL, so that the initial rate of the metabolism could be practically measured (data not shown). (Fig. 2D ), which were also 14 amu less than the corresponding product ions of BILR 516. So it is likely that M17 is formed after demethylation on the diazepinone ring from BILR 516.
Identification of Metabolites of BILR 355 in Clinical
The retention times and characteristic product ions of the parent and all metabolite are listed in Fig. 3 . The names of the standards are also listed in the final column in Table 2 and next to the metabolite names in Fig. 3 .
This article has not been copyedited and formatted. The final version may differ from this version. The levels of BILR 516 were surprisingly high at steady state, exceeding levels of parent drug.
The mean plasma concentration-time profiles of BILR 516 on day 1 and steady state are plotted in Fig. 4 . The BILR 355 profiles are also shown in Fig. 4 for comparison purposes (Huang et al., 2009 ). The calculated C max , area under the plasma concentration-time curve over the dosing interval (AUC0-τ), and T 1/2 of BILR 516 and BI 212578, and comparison of these values with those obtained for BILR 355 (Huang et al., 2009 ) are shown in Table 3 .
This article has not been copyedited and formatted. The final version may differ from this version. proposed as an explanation for the low systemic exposure and short half-life following oral administration to humans (Huang et al., 2008) . A favorable PK profile, with increased systemic exposure, was achieved after concomitant administration of the CYP3A inhibitor RTV (Huang et al., 2008) as seen with other HIV drugs (Hull and Montaner, 2011 ). An unexpected consequence of the inhibition of this primary clearance pathway was a metabolic switching leading to the formation of a disproportionate human metabolite.
First, the in vitro metabolism of BILR 355 was evaluated in HLMs. As summarized in Table   1 , the calculated intrinsic clearance of BILR 355 by HLMs appears to be fairly high. The average CL h /Q h from four HLM lots was 82%, indicating that BILR 355 may go through extensive Phase I metabolism in vivo. The apparent K m values for BILR 355 metabolism ranged from 0.63 µM to 1.14 µM with a mean value of 0.79 µM. In the clinical Phase Ia study with administration of single doses of BILR 355 from 12.5 mg to 100 mg, C max ranged from 14.8 ng/mL (0.03 µM) to 937 ng/mL (2.12 µM) (Huang et al., 2008) , which bracketed the range of apparent K m values shown above. Therefore, it was not surprising to see the mean exposure (AUC 0-∞ ) increase superproportionally (71.8 ng.h/mL to 1,310 ng.h.mL) and the mean apparent clearance (CL/F) decrease (246 to 79.2 L/h) over this range of doses in the Phase Ia study (Huang et al., 2008) .
The observed nonlinearity in AUC 0-∞ and CL/F is likely due to saturation of the metabolism of
This article has not been copyedited and formatted. The final version may differ from this version. structures of ten of these metabolites were confirmed based on comparison with authentic standards. While almost all of these metabolites were minor based on quantitation using authentic standards or peak area estimations for metabolites without authentic standards, there was one metabolite found at substantial levels, BILR 516. This metabolite was not observed in human plasma when BILR 355 was administered along (Boehringer Ingelheim Pharmaceuticals, Inc., Data on file).
BILR 516 accumulated in humans over time (Fig. 4) which was attributable to its long T 1/2 (54.5 h) ( Table 3 ). The T 1/2 of BILR 516 is significantly longer than the T 1/2 of the parent compound (14.7 h) ( Table 3) . As a result, the exposure of BILR 516 was even higher than the exposure of the parent drug at steady-state (Fig. 4) . Since the exposure of BILR 516 was greater than 10% of the total drug-related materials, it was identified as a major human metabolite (FDA, 2008 
